{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2085, 
        2099
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2278, 
        2292
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2561, 
        2575
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2771, 
        2785
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2982, 
        2996
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3104, 
        3127
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1993, 
        2020
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        446, 
        475
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1498, 
        1533
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2066, 
        2074
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2259, 
        2267
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2470, 
        2476
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2542, 
        2550
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2752, 
        2760
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2963, 
        2971
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2075, 
        2084
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2268, 
        2277
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2477, 
        2493
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2551, 
        2560
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2761, 
        2770
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2972, 
        2981
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2042, 
        2052
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2236, 
        2245
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2446, 
        2456
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2519, 
        2528
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2730, 
        2738
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2940, 
        2949
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2022, 
        2023
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 11^9311^MOH|PIMS|CCO|20160502113218|A85A9D8A1D8B480AFF287A54FEE0F15AC36DC6DE|ORU^R01|99999999999999999999|P|2.5|||||\nPID|1||^^^^MRN^HOSPITAL 11&9999&MOH~9999999999&GE&ON^^^^JHN||XXXXXXX^XXXXXXX^||99999999|M||||||||||||||||||||||N|\nOBR|1||BZ00604535|11529-5^Surgical Pathology Study Report^LN^BX^Biopsy^L|||20160425|||73908^XXXXXXX^XXXXX^XXXXX^^XX.||||||||||||20160502|||F|||||||99999^XXXXXXX^XXXX^XXXXXX^^XX|\n\n\n\n\n\n\n\nPath report.gross description\n\n1.Specimen consists of 2 tan tissue coresnE\\measuring 15 and 20 mm and 1 fragment measuringnE\\in total 2 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\2.Specimen consists of 2 tan tissue coresnE\\measuring 10 and 22 mm and 4 fragments measuringnE\\in total 12 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\3.Specimen consists of 2 tan tissue coresnE\\measuring 12 and 15 mm and 2 fragments measuringnE\\in total 2 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\4.Specimen consists of 2 tan tissue coresnE\\measuring 18 and 19 mm in length by less than 1nE\\mm in diameter and no fragments. Embedded innE\\toto.nE\nE\\5.Specimen consists of 2 tan tissue coresnE\\measuring 16 and 18 mm and 1 fragment measuringnE\\in total 1 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\6.Specimen consists of 2 tan tissue coresnE\\measuring 12 and 16 mm and 5 fragments measuringnE\\in total 6 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\\\n\n\nPath report.microscopic observation\n\nTumour TypenE\\Adenocarcinoma, conventional typenE\nE\\ExtentnE\\# sites involved/total sites  5 / 6nE\\# cores involved/total cores  10 / 12nE\\Overall % tissue involved  \\R\\70%nE\\% involvement in mostnE\\extensively involved core  100%nE\nE\\GleasonnE\\Overall Gleason Score (1?, worst)7 (4, 3)nE\\Highest Gleason Score (any site)7 (4, 3)nE\\% Gleason patterns 4, 5  60-70%nE\nE\\OthernE\\Perineural invasion     PresentnE\\Periprostatic fat invasion  Not identifiednE\\\n\n\nPath report.final diagnosis\n\n1.BIOPSY, PROSTATE (RIGHT BASE LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 7/10 (PRIMARY 4, SECONDARY 3); 1 CORE AND 1nE\\FRAGMENT INVOLVED; ABOUT 80% TISSUE INVOLVEMENT.nE\nE\\2.BIOPSY, PROSTATE (RIGHT MID LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 7/10 (PRIMARY 4, SECONDARY 3); 2/2 CORESnE\\INVOLVED; ABOUT 70% TISSUE INVOLVEMENT;nE\\FOCAL PERINEURAL INVASION.nE\nE\\3.BIOPSY, PROSTATE (RIGHT APEX LATERAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\4.BIOPSY, PROSTATE (LEFT BASE LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 7/10 (PRIMARY 4, SECONDARY 3); 2/2 CORESnE\\INVOLVED; ABOUT 100% TISSUE INVOLVEMENT;nE\\FOCAL PERINEURAL INVASION.nE\nE\\5.BIOPSY, PROSTATE (LEFT MID LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 7/10 (PRIMARY 4, SECONDARY 3); 2/2 CORESnE\\INVOLVED; ABOUT 100% TISSUE INVOLVEMENT;nE\\FOCAL PERINEURAL INVASION.nE\nE\\6.BIOPSY, PROSTATE (LEFT APEX LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 7/10 (PRIMARY 4, SECONDARY 3); 2/2 CORESnE\\INVOLVED; ABOUT 20% TISSUE INVOLVEMENT.nE\nE\\\n\n\nPath report.relevant Hx\n\nNot providednE\nE\\Not providednE\\\n\n\n"
}